In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...
Ametris (formerly ActiGraph) has launched its second Digital Endpoint Collaboration Outcome Development (DECODE) working group for the purpose of enhancing drug development for obesity. The ...
When pharmaceutical companies develop a novel drug for the market, several steps are required to assess and regulate its safety, effectiveness, manufacturability, and reliability. These processes, and ...
TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.
TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment ...
The pharmaceutical industry invests heavily in technologies—$57.4 billion in 2022 alone—to discover new therapies to treat our greatest health challenges. Yet drug development teams are still using ...
Companies operating in the pharmaceutical and biotech sectors must evaluate a range of critical factors prior to partnering with a contract development and manufacturing organization (CDMO). Selecting ...
Two formative experiences shaped Craig Crews’ path into drug development. First, when he was still a child, his grandmother died from cancer at just 52 years old. “At the time, there weren’t very many ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback